Clinical Trial Update: MNPR-101-PCTA-177Lu Expanded Access Program (EAP) for Patients With Solid Tumor Cancer

View source ↗

Summary

Monopar Therapeutics provides an Expanded Access Program for MNPR-101-PCTA-177Lu in patients with solid tumors, with access currently available. The entry indic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Solid Tumor

Drugs mentioned

• MNPR-101-PCTA-177Lu

Snippet

Sponsor: Monopar Therapeutics | Conditions: Cancer, Solid Tumor | Status: AVAILABLE